Relation between different treatment modalities and genomic damage of end-stage renal failure patients

Kidney and Blood Pressure Research

Volumn 29, Issue 1, 2006, Pages 10-17

  Kobras, K ^a   Schupp, N ^a   Nehrlich, K ^a   Adelhardt, M ^a   Bahner, U ^b   Vienken, J ^c   Heidland, A ^a   Sebekova, K ^d   Stopper, H ^a,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Kuratorium for Dialysis and Kidney Transplantation   (Germany)

^c FRESENIUS MEDICAL CARE   (Germany)

^d SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^e NONE   (Germany)

Author keywords

Advanced glycation end products; Comet assay; Genomic damage; Hemodiafiltration; Hemodialysis; Micronuclei

Indexed keywords

ADVANCED GLYCATION END PRODUCT; IMIDAZOLINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMET ASSAY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DNA DAMAGE; FEMALE; FLUORESCENCE; GENETIC DAMAGE; GENOTOXICITY; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LONGITUDINAL STUDY; MALE; MICRONUCLEUS TEST; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

AGED; COMET ASSAY; DNA DAMAGE; GENOME, HUMAN; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMODIAFILTRATION; HUMANS; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; LYMPHOCYTES; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME; UREMIA;

EID: 33745043316     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092482     Document Type: Article

References (22)

1. Herzog C, Ma J, Collins A: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
2. Maisonneuve P, Agodoa L, Gellert R, Stewart J, Buccianti G, Lowenfels A, Wolfe R, Jones E, Disney A, Briggs D, McCredie M, Boyle P: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354:93-99.
3. Teschner M, Garte C, Ruckle-Lanz H, Mader U, Stopper H, Klassen A, Heidland A: Incidence and spectrum of malignant disease among dialysis patients in North Bavaria. Dtsch Med Wochenschr 2002;127:2497-2502.
4. Stopper H, Meysen T, Bockenforde A, Bahner U, Heidland A, Vamvakas S: Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Am J Kidney Dis 1999;34:433-437.
5. Stopper H, Boullay F, Heidland A, Vienken J, Bahner U: Comet-assay analysis identifies genomic damage in lymphocytes of uremic patients. Am J Kidney Dis 2001;38:296-301.
6. Tarng D-C, Tsai T-J, Chen W-T, Liu T-Y, Wei Y-H: Effect of human OGG1 1245C→1G gene polymorphism on 8-hydroxy-2′-deoxyguanosine levels of leukocyte DNA among patients undergoing chronic hemodialysis. J Am Soc Nephrol 2001;12:2338-2347.
7. Hayakawa M, Hattori K, Sugiyama S, Ozawa T: Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochem Biophys Res Commun 1992;198:979-985.
8. Martinet W, Knaapen M, De Meyer G, Herman A, Kockx M: Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002;106:927-932.
9. Malachi T, Zevin D, Gafter U, Chagnac A, Slor H, Levi J: DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 1993;44:385-389.
10. Vamvakas S, Bahner U, Becker P, Steinle A, Gotz R, Heidland A: Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant Proc 1996;28:3468-3473.
11. Canaud B, Leray-Moragues H, Bosc J, Leblanc M: Ultrafiltration and convective-based dialysis modalities: new trends and applications for renal replacement therapy in ESRD patients. Nephrol Dial Transplant 1999;14:98-105.
12. Hagmar L, Stromberg U, Tinnerberg H, Mikoczy Z: Epidemiological evaluation of cytogenetic biomarkers as potential surrogate end-points for cancer. IARC Sci Publ 2004;157:207-215.
13. Fenech M: The in vitro micronucleus technique. Mutat Res 2000;455:81-95.
14. Miller B, Potter-Locher F, Seelbach A, Stopper H, Utesch D, Madle S: Evaluation of the in vitro micronucleus test as an alternative to the in vitro chromosomal aberration assay: position of the GUM Working Group on the in vitro micronucleus test. Gesellschaft für Umwelt-Mutations-Forschung. Mutat Res 1998;410:81-116.
15. Stopper H, Müller SO: Micronuclei as a biological endpoint for genotoxicity: a minireview. Toxicol in vitro 1997;11:661-667.
16. Kassie F, Parzefall W, Knasmuller S: Single cell gel electrophoresis assay: a new technique for human biomonitoring studies. Mutat Res 2000;463:13-31.
17. Stopper H, Schinzel R, Sebekova K, Heidland A: Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 2003;190:151-156.
18. Singh N, McCoy M, Tice R, Schneider EA: Simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-191.
19. Niwa T, Katsuzaki T, Miyazak S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997;99:1272-1280.
20. Münch G, Mayer S, Michaelis J, Hipkiss A, Riederer P, Muller R, Neumann A, Schinzel R, Cunningham A: Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta 1997;1360:17-29.
21. Schupp N, Ahmed N, Thornalley P, Nerlich K, Braun J, Vienken J, Heidland A, Stopper H: Genomic damage and content of free and protein-bound AGEs in end-stage renal failure: influence of different dialysis modalities. J Artif Org 2004;27:582.
22. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002;17:1045-1049.